EUVIMEDEUVIMED entdecken
Crossref

Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety

Vasilis Petrakis, Periklis Panagopoulos, Stella Papachristou, Nikolaos Papanas, Irene Terzi, Grigorios Trypsianis, Dimitrios Papazoglou

AIDS Research and Human Retroviruses · 01.09.2020 · 36 (9) · 697-702

DOI: 10.1089/aid.2019.0280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS Research and Human Retroviruses, erschienen am 01.09.2020. Verfasst von Vasilis Petrakis und 6 weiteren Autor:innen. Beteiligte Einrichtung: HIV Unit, Democritus University of Thrace, University General Hospital of Alexandroupolis, Alexandroupoli, Greece. Hauptthemen laut MEDLINE: Anti-HIV Agents, Cardiovascular Diseases, HIV Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiretroviral treatment based on tenofovir alafenamide fumarate (TAF) is increasingly recommended, as it maintains the viral suppression and improves renal function and bone density in comparison with tenofovir disoproxil fumarate (TDF). We carried out a retrospective cohort study including experienced patients who switched treatment from TDF to TAF. Serum lipids and glucose, renal function, body mass index (BMI), and cardiovascular risk were evaluated before and 3 and 6 months after the initiation of TAF-based treatment. We identified 85 patients on TAF-based treatment. The majority were men (82.9%), smokers (70%), and older than 40 years. Significant increases in lipids and BMI were noted, but cardiovascular risk remained

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsCardiovascular DiseasesHIV InfectionsAlanineFemaleFumaratesHumansKidneyMaleRetrospective StudiesTenofovir

Stichwörter der Autor:innen

HIVtenofovirtenofovir disoproxil fumaratetenovofir alafenamide fumarate

Substanzen

Anti-HIV AgentsFumaratesTenofovirtenofovir alafenamideAlanine

Autor:innen und Institutionen

  • HIV Unit, Democritus University of Thrace, University General Hospital of Alexandroupolis, Alexandroupoli, Greece.
  • Department of Medical Statistics, Democritus University of Thrace, Alexandroupoli, Greece.

Zitieren

APA

Petrakis, V., Panagopoulos, P., Papachristou, S., Papanas, N., Terzi, I., Trypsianis, G., & Papazoglou, D. (2020). Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety. AIDS Research and Human Retroviruses, 36(9), 697-702. https://doi.org/10.1089/aid.2019.0280

Vancouver

Petrakis V, Panagopoulos P, Papachristou S, Papanas N, Terzi I, Trypsianis G, et al. Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety. AIDS Research and Human Retroviruses. 2020;36(9):697-702. doi:10.1089/aid.2019.0280

BibTeX
@article{Petrakis2020,
  author = {Petrakis, Vasilis and Panagopoulos, Periklis and Papachristou, Stella and Papanas, Nikolaos and Terzi, Irene and Trypsianis, Grigorios and Papazoglou, Dimitrios},
  title = {Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety},
  journal = {AIDS Research and Human Retroviruses},
  year = {2020},
  volume = {36},
  number = {9},
  pages = {697--702},
  doi = {10.1089/aid.2019.0280}
}
Kostenlos starten →